Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Significance of RT-qPCR-Based Measurable Residual Disease for Optimizing the Treatment of Pediatric Acute Myeloid Leukemia

Evangelia Antoniou, Lina Marie Hoffmeister, Nils Von Neuhoff, Dirk Reinhardt, Markus Schneider, Stephanie Sendker

Blood (2024) 144 (Supplement 1): 228.

https://doi.org/10.1182/blood-2024-208718

Published: 2024

Journal Articles

Comprehensive Analysis of Target and Immune Checkpoint Markers in Pediatric AML

Stephanie Sendker, Jens Gehlen, Tabea Ziedrich, Evangelia Antoniou, Markus Schneider, Nils Von Neuhoff, Dirk Reinhardt, Lina Marie Hoffmeister

Blood (2024) 144 (Supplement 1): 4322.

https://doi.org/10.1182/blood-2024-208614

Published: 2024

Journal Articles

Characteristics of FLT3 -ITD and Efficacy of Sorafenib Treatment in Pediatric AML: A Report from AML-BFM Study Group

Evangelia Antoniou, Annika Puschnig, Lina Marie Hoffmeister, Amani Awada, Nils Von Neuhoff, Markus Schneider, Dirk Reinhardt, Naghmeh Niktoreh

Blood (2023) 142 (Supplement 1): 4217.

https://doi.org/10.1182/blood-2023-187465

Published: 2023

Journal Articles

Nucleophosmin (NPM1) Type D Genotype Is Associated with Distinct Outcome in Acute Myeloid Leukemia - an AIEOP-BFM and COG-SWOG Intergroup Collaboration

Martina Pigazzi, Claudia Tregnago, Rhonda E Ries, Maddalena Benetton, Todd A. Alonzo, Nicolas Duployez, Edwin Sonneveld, Jonas Abrahamsson, Linda Fogelstrand, Nils Von Neuhoff, Henrik Hasle, Dirk Reinhardt, Franco Locatelli, Soheil Meshinchi

Blood (2023) 142 (Supplement 1): 840.

https://doi.org/10.1182/blood-2023-181872

Published: 2023

Journal Articles

RAS Pathway Alterations in Pediatric AML Patients

Kevin Hai-Ning Lu, Lina Hoffmeister, Eser Orhan, Markus Schneider, Katharina Waack, Helmut Hanenberg, Nils von Neuhoff, Dirk Reinhardt

Blood (2022) 140 (Supplement 1): 6110–6111.

https://doi.org/10.1182/blood-2022-170747

Published: 2022

Journal Articles

RUNX1 Mutations Have Distinct Prognostic and Clinical Implication in Pediatric AML: Results of the AML-BFM Study Group

Stephanie Sendker, Markus Schneider, Amani Awada, Eser Orhan, Michael Sendker, Lina Hoffmeister, Evangelia Antoniou, Dirk Reinhardt, Nils Von Neuhoff

Blood (2022) 140 (Supplement 1): 9110–9112.

https://doi.org/10.1182/blood-2022-167465

Published: 2022

Journal Articles

Revision of Complete Remission Criteria in Pediatric AML

Evangelia Antoniou, Annika Puschnig, Katharina Waack, Carolin Augsburg, Christel Katerkamp, Denise Kondryn, Tabea Ziedrich, Nils von Neuhoff, Dirk Reinhardt, Stephanie Sendker

Blood (2022) 140 (Supplement 1): 1016–1017.

https://doi.org/10.1182/blood-2022-170648

Published: 2022

Journal Articles

Molecular Relapse in Pediatric AML: Clinical Relapse May be Predicted By Increasingin MRD Level - Experiences from Real-World Data in Patients with Inv(16), t(8;21), t(9;11), t(10;11) or NPM1

Katharina Waack, Katharina Andernacht, Christiane Walter, Markus Schneider, Nils Von Neuhoff, Sophia Hahn, Amani Awada, Dirk Reinhardt

Blood (2022) 140 (Supplement 1): 6326–6327.

https://doi.org/10.1182/blood-2022-169495

Published: 2022

Journal Articles

Failures and Successes in Pediatric Patients with Acute Myeloid Leukemia with First Relapse: A Large International Report on Current Treatment Strategies and Outcome

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-141774

Published: 2020

Journal Articles

Impact of Minimal Residual Disease (MRD) Assessed before Transplantation on the Outcome of Children with Acute Myeloid Leukemia Given an Allograft: A Retrospective Study By the I-BFM Study Group

Martina Pigazzi, PhD, Maddalena Benetton, Christiane Walter, MSc, Maria Hansen, Anne-Sofie Skou, MD, Ambra Da Ros, Anna Marchetti, Katia Polato, Mattia Belloni, Claudia Tregnago, PhD, Jonas Abrahamsson, MD PhD, Linda Fogelstrand, Nils Von Neuhoff, PhD, Dirk Reinhardt, MDPhD, Henrik Hasle, PhD, Franco Locatelli, MD, Pietro Merli, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-137424

Published: 2020

Journal Articles

Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group

Mareike Rasche, MD, Emma Steidel, Martin Zimmermann, Jean-Pierre Bourquin, MD PhD, Heidrun Boztug, Iveta Janotová, Edward A. Kolb, MD, Thomas Lehrnbecher, Nils Von Neuhoff, PhD, Naghmeh Niktoreh, Nora Muehlegger, Lucie Sramkova, MD, Jan Stary, MD PhD, Christiane Walter, MSc, Ursula Creutzig, MD PhD, Michael Dworzak, MD PhD, Dirk Reinhardt, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-139317

Published: 2020

Journal Articles

Impact of a Risk-Adapted Treatment Approach in Pediatric AML: A Report of the AML-BFM Registry 2012

Mareike Rasche, MD, Emma Steidel, Denise Kondryn, Nils Von Neuhoff, PhD, Lucie Sramkova, MD, Ursula Creutzig, MD, Michael Dworzak, MD, Dirk Reinhardt, MD

Blood (2019) 134 (Supplement_1): 293.

https://doi.org/10.1182/blood-2019-130969

Published: 2019

Journal Articles

Induction of a Leukemic Bone Marrow Niche Mediated By TGFB1 of Leukemic Blasts in Pediatric Acute Mekaryoblastic Leukemia: Results of an in Vitro and In Vivo Analysis

Theresa Hack, MSc, Stefanie Bertram, MD, Guntram Büsche, MD, Helmut Hanenberg, MD, Ludger Klein-Hitpass, PhD, Nils Von Neuhoff, PhD, Dirk Reinhardt, MD, Markus Schneider, PhD, Mareike Rasche, MD

Blood (2019) 134 (Supplement_1): 3734.

https://doi.org/10.1182/blood-2019-126536

Published: 2019

Journal Articles

Mutational Landscape of Pediatric Acute Myeloid Leukemia: A Report of the AML-BFM Study Group with a Targeted NGS Approach in 525 Patients Integrating De Novo, Relapsed and Secondary AML

Christiane Walter, MSc, Markus Schneider, PhD, Nils Von Neuhoff, PhD, Helmut Hanenberg, MD, Dirk Reinhardt, MD, Mareike Rasche, MD

Blood (2019) 134 (Supplement_1): 1398.

https://doi.org/10.1182/blood-2019-129778

Published: 2019

Journal Articles

Measurable Residual Disease Assessment By qPCR in Peripheral Blood Is an Informative Tool for Disease Surveillance in Childhood Acute Myeloid Leukemia

Kristian Juul-Dam, MD, Hans Beier Ommen, Charlotte Guldborg Nyvold, Christiane Walter, Helen Vålerhaugen, Veli Kairisto, Jonas Abrahamsson, Sofie Johansson Alm, Kirsi Jahnukainen, Birgitte Lausen, Dirk Reinhardt, Bernward Zeller, Nils Von Neuhoff, Linda Fogelstrand, MD PhD, Henrik Hasle, MD

Blood (2018) 132 (Supplement 1): 2754.

https://doi.org/10.1182/blood-2018-99-119642

Published: 2018

Journal Articles

Response to Front-Line Imatinib Treatment in Children and Adolescents with CML - Data from a Large Pediatric Cohort

Blood (2017) 130 (Supplement 1): 898.

https://doi.org/10.1182/blood.V130.Suppl_1.898.898

Published: 2017

Journal Articles

Amplicon Based Panel Targeted Resequencing Identified ZRSR2 As a Potential New Favorable Marker in Pediatric AML

Christiane Walter, MSc, Zhenyu Xu, PhD, Martin Zimmermann, PhD, Dirk Reinhardt, MD PhD, Nils Von Neuhoff, PhD

Blood (2016) 128 (22): 2905.

https://doi.org/10.1182/blood.V128.22.2905.2905

Published: 2016

Journal Articles

Evaluation of Genetic Mutations in Plasma Exosomes As a Biomarker Tool for Detecting the Clonal Evolution of Leukemic Cells in Pediatric AML

Fabienne Kunz, Katarina Reinhardt, PhD, Nils Von Neuhoff, PhD, Karl Welte, MD, Dirk Reinhardt, MD PhD, Basant Kumar Thakur, PhD

Blood (2016) 128 (22): 1711.

https://doi.org/10.1182/blood.V128.22.1711.1711

Published: 2016

Journal Articles

The Novel FLT3-N676K Mutant Induces Acute Leukemia Independently of the Inv(16) Chimeric Gene CBFB-MYH11

Kezhi Huang, Min Yang, Zengkai Pan, Florian H. Heidel, MD, Michaela Scherr, PhD, Matthias Eder, MD, Thomas Fischer, MD, Guntram Buesche, MD, Nils von Neuhoff, PhD, Arnold Ganser, MD, Zhixiong Li, MD

Blood (2015) 126 (23): 1383.

https://doi.org/10.1182/blood.V126.23.1383.1383

Published: 2015

Journal Articles

Analysis of WT1 Mutations and Combined Aberrations in Childhood Acute Myeloid Leukemia using Whole Exome Sequencing

Nils von Neuhoff, PhD, Peter Husemann, PhD, Robert Geffers, PhD, Christiane Walter, M.Sc., Christine von Neuhoff, MD, Martin Zimmermann, PhD, Brigitte Schlegelberger, MD, Dirk Reinhardt, MD PhD

Blood (2014) 124 (21): 2340.

https://doi.org/10.1182/blood.V124.21.2340.2340

Published: 2014

NARROW

Significance of RT-qPCR-Based Measurable Residual Disease for Optimizing the Treatment of Pediatric Acute Myeloid Leukemia

Comprehensive Analysis of Target and Immune Checkpoint Markers in Pediatric AML

Characteristics of FLT3 -ITD and Efficacy of Sorafenib Treatment in Pediatric AML: A Report from AML-BFM Study Group

Nucleophosmin (NPM1) Type D Genotype Is Associated with Distinct Outcome in Acute Myeloid Leukemia - an AIEOP-BFM and COG-SWOG Intergroup Collaboration

RAS Pathway Alterations in Pediatric AML Patients

RUNX1 Mutations Have Distinct Prognostic and Clinical Implication in Pediatric AML: Results of the AML-BFM Study Group

Revision of Complete Remission Criteria in Pediatric AML

Molecular Relapse in Pediatric AML: Clinical Relapse May be Predicted By Increasingin MRD Level - Experiences from Real-World Data in Patients with Inv(16), t(8;21), t(9;11), t(10;11) or NPM1

Failures and Successes in Pediatric Patients with Acute Myeloid Leukemia with First Relapse: A Large International Report on Current Treatment Strategies and Outcome

Impact of Minimal Residual Disease (MRD) Assessed before Transplantation on the Outcome of Children with Acute Myeloid Leukemia Given an Allograft: A Retrospective Study By the I-BFM Study Group

Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group

Impact of a Risk-Adapted Treatment Approach in Pediatric AML: A Report of the AML-BFM Registry 2012

Induction of a Leukemic Bone Marrow Niche Mediated By TGFB1 of Leukemic Blasts in Pediatric Acute Mekaryoblastic Leukemia: Results of an in Vitro and In Vivo Analysis

Mutational Landscape of Pediatric Acute Myeloid Leukemia: A Report of the AML-BFM Study Group with a Targeted NGS Approach in 525 Patients Integrating De Novo, Relapsed and Secondary AML

Measurable Residual Disease Assessment By qPCR in Peripheral Blood Is an Informative Tool for Disease Surveillance in Childhood Acute Myeloid Leukemia

Response to Front-Line Imatinib Treatment in Children and Adolescents with CML - Data from a Large Pediatric Cohort

Amplicon Based Panel Targeted Resequencing Identified ZRSR2 As a Potential New Favorable Marker in Pediatric AML

Evaluation of Genetic Mutations in Plasma Exosomes As a Biomarker Tool for Detecting the Clonal Evolution of Leukemic Cells in Pediatric AML

The Novel FLT3-N676K Mutant Induces Acute Leukemia Independently of the Inv(16) Chimeric Gene CBFB-MYH11

Analysis of WT1 Mutations and Combined Aberrations in Childhood Acute Myeloid Leukemia using Whole Exome Sequencing

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only